

【英文】

1. Koizumi F, Ohnishi A, Takemura H, Okubo S, Kagami T.  
Effective monitoring of concentrations of ofloxacin in saliva of patients with chronic respiratory tract infections. *Anti Micro Agent chemother.* 1994; 38(5): 1140-1143.
2. Inoue T, Ohnishi A, Matsuo A, Kawai B, Kunihiro N, Tada Y, Koizumi F, Chau T, Okada K, Yamamura Y, Tanaka T.  
Therapeutic and diagnostic potential of vasopressin-2 antagonist for impaired water handling in cirrhosis. *Clin Pharmacol Ther.* 1998; 63(5): 561-570.
3. Usuda J, Saijo N, Fukuoka K, Fukumoto H, Kuh H-J, Nakamura T, Koh Y, Suzuki T, Koizumi F, Tamura T, Kato H, Nishio K.  
Molecular determinants of UCN-01-induced growth inhibition in human lung cancer cells. *Int J Cancer.* 2000; 85(2): 275-280.
4. Koizumi F, Murakami M, Kageyama H, Katashima M, Terakawa M, Ohnishi A.  
Smoking accelerates absorption of inhaled neutrophil elastase inhibitor FK706. *Clin Pharmacol Ther.* 1999; 66(5): 501-508.
5. Kanzawa F, Koizumi F, Koh Y, Nakamura T, Tatsumi Y, Fukumoto H, Saijo N, Yoshioka T, Nishio K.  
In vitro synergistic interactions between the cisplatin analogue nedaplatin and the DNA topoisomerase I inhibitor irinotecan and the mechanism of this interaction. *Clin Cancer Res.* 2001; 7(1): 202-209.
6. Nakamura T, Koizumi F, Kaneko N, Tamura T, Chiwaki F, Koh Y, Akutagawa S, Saijo N, Nishio K.  
Reversal of Cisplatin Resistance by the 1,4-Benzothiazepine Derivative, JTV-519. *Jpn. J. Cancer Res.* 2001; 92(6): 597-602.
7. Nishiyama N, Koizumi F, Okazaki S, Matsumura Y, Nishio K.  
Differential gene expression profile between PC-14 cells treated with free cisplatin-incorporated polymeric micelles. *Bioconjug Chem.* 2003; 14(2): 449-457.
8. Tsunoda T, Koh Y, Koizumi F, Tsukiyama S, Ueda H, Taguchi F, Saijo N, Nishio K.  
Differential gene expression profiles and identification of the genes relevant to clinicopathologic factors in colorectal cancer selected by cDNA array method in combination with principal component analysis. *Int J Oncol* 2003; 23(1): 49-59.
9. Koizumi F, Kanzawa F, Ueda Y, Koh Y, Tsukiyama S, Taguchi F, Tamura T, Saijo N, Nishio K.  
Synergistic interaction between the EGFR tyrosine kinase inhibitor ZD1839 (Iressa) and the DNA topoisomerase I inhibitor CPT-11 (Irinotecan) in human colorectal cancer cells. *Int J Cancer* 2004; 108 (3): 464-472.
10. Taguchi F, Koh Y, Koizumi F, Tamura T, Saijo N, Nishio K.  
Anticancer effects of ZD6474, a VEGF receptor tyrosine kinase inhibitor, in gefitinib ("Iressa")-sensitive and resistant xenograft models. *Cancer Sci.* 2004; 95(12):984-989.
11. Koizumi F, Shimoyama T, Taguchi F, Saijo N, Nishio K.  
Establishment of a human non-small cell lung cancer cell line resistant to gefitinib. *Int J Cancer.* 2005 Aug 10;116(1):36-44.
12. Yanagihara K, Takigahira M, Tanaka H, Komatsu T, Fukumoto H, Koizumi F, Nishio K, Ochiya T, Ino Y, Hirohashi S.  
Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer. *Cancer Sci.* 2005; 96(6): 323-332.

13. Uchino H, Matsumura Y, Negishi T, Koizumi F, Hayashi T, Honda T, Nishiyama N, Kataoka K, Naito S, Kakizoe T.  
Cisplatin-incorporating polymeric micelles (NC-6004) can reduce nephrotoxicity and neurotoxicity of cisplatin in rats. *Br J Cancer*. 2005; 93(6): 678-687.
14. Arao T, Yanagihara K, Takigahira M, Takeda M, Koizumi F, Shiratori Y, Nishio K.  
ZD6474 inhibits tumor growth and intraperitoneal dissemination in a highly metastatic orthotopic gastric cancer model. *Int J Cancer*. 2006; 118(2): 483-489.
15. Shimoyama T, Hamano T, Natsume T, Koizumi F, Kiura K, Tanimoto M, Nishio K.  
Reference profiling of the genomic response induced by an antimicrotubule agent, TZT-1027 (Soblidotin), in vitro. *Pharmacogenomics J*. 2006; 6(6): 388-396.
16. Shimoyama T, Koizumi F, Fukumoto H, Kiura K, Tanimoto M, Saijo N, Nishio K.  
Effects of different combinations of gefitinib and irinotecan in lung cancer cell lines expressing wild or deletional EGFR. *Lung Cancer*. 2006; 53(1): 13-21. Epub 2006 May 19.
17. Negishi T, Koizumi F, Uchino H, Kuroda J, Kawaguchi T, Naito S, Matsumura Y.  
NK105, a paclitaxel-incorporating micellar nanoparticle, is a more potent radiosensitising agent compared to free paclitaxel. *Br J Cancer*. 2006; 95(5): 601-606.
18. Koizumi F, Kitagawa M, Negishi T, Onda T, Matsumoto S, Hamaguchi T, Matsumura Y.  
Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors. *Cancer Res*. 2006; 66(20): 10048-1056.
19. Kimura H, Suminoe M, Kasahara K, Sone T, Araya T, Tamori S, Koizumi F, Nishio K, Miyamoto K, Fujimura M, Nakao S.  
Evaluation of epidermal growth factor receptor mutation status in serum DNA as a predictor of response to gefitinib (IRESSA). *Br J Cancer*. 2007; 97(6): 778-784.
20. Yamada Y, Arao T, Gotoda T, Taniguchi H, Oda I, Shirao K, Shimada Y, Hamaguchi T, Kato K, Hamano T, Koizumi F, Tamura T, Saito D, Shimoda T, Saka M, Fukagawa T, Katai H, Sano T, Sasako M, Nishio K.  
Identification of prognostic biomarkers in gastric cancer using endoscopic biopsy samples. *Cancer Sci*. 2008; 99(11):2193-2199.
21. Katanasaka Y, Ida T, Asai T, Shimizu K, Koizumi F, Maeda N, Baba K, Oku N.  
Antiangiogenic cancer therapy using tumor vasculature-targeted liposomes encapsulating 3-(3,5-dimethyl-1H-pyrrol-2-ylmethylene)-1,3-dihydro-indol-2-one, SU5416. *Cancer Lett*. 2008; 270(2):260-268.
22. Fukai J, Nishio K, Itakura T, Koizumi F.  
Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III. *Cancer Sci*. 2008; 99: 2062-2069.
23. Nakajima TE, Yasunaga M, Kano Y, Koizumi F, Kato K, Hamaguchi T, Yamada Y, Shirao K, Shimada Y, Matsumura Y.  
Synergistic antitumor activity of the novel SN-38-incorporating polymeric micelles, NK012, combined with 5-fluorouracil in a mouse model of colorectal cancer, as compared with that of irinotecan plus 5-fluorouracil. *Int J Cancer*. 2008; 122(9): 2148-2153.
24. Sumitomo M, Koizumi F, Asano T, Horiguchi A, Ito K, Asano T, Kakizoe T, Hayakawa M, Matsumura Y.  
Novel SN-38-incorporated polymeric micelle, NK012, strongly suppresses renal cancer progression. *Cancer Res*. 2008; 68(6): 1631-1635.
25. Matsumoto K, Shimizu C, Arao T, Andoh M, Katsumata N, Kohno T, Yonemori K, Koizumi F, Yokote H, Aogi K, Tamura K, Nishio K, Fujiwara Y.  
Identification of predictive biomarkers for response to trastuzumab using plasma FUCA activity and N-glycan identified by MALDI-TOF-MS. *J Proteome Res*. 2009; 8: 457-462.

26. Kawaishi M, Fujiwara Y, Fukui T, Kato T, Yamada K, Ohe Y, Kunitoh H, Sekine I, Yamamoto N, Nokihara H, Watabe T, Shimoda Y, Arao T, Nishio K, Tamura T, Koizumi F. Circulating endothelial cells in non-small cell lung cancer patients treated with carboplatin and paclitaxel. *J Thorac Oncol*. 2009; 4: 208-213.
27. Fukui T, Kodera Y, Nishio K, Masuda N, Tamura T, Koizumi F. Synergistic interactions between the synthetic retinoid tamibarotene and glucocorticoids in human myeloma cells. *Cancer Sci*. 2009; 100(6): 1137-1143.
28. Yamamoto Y, Kosaka N, Tanaka M, Koizumi F, Kanai Y, Mizutani T, Murakami Y, Kuroda M, Miyajima A, Kato T, Ochiya T. MicroRNA-500 as a potential diagnostic marker for hepatocellular carcinoma. *Biomarkers*. 2009; 14(7): 529-538.
29. Katanasaka Y, Ishii T, Asai T, Naitou H, Maeda N, Koizumi F, Miyagawa S, Ohashi N, Oku N. Cancer antineovascular therapy with liposome drug delivery systems targeted to BiP/GRP78. *Int J Cancer*. 2010; 127(11): 2685-2698.
30. Taguchi F, Kodera Y, Katanasaka Y, Yanagihara K, Tamura T, Koizumi F. Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination. *Invest New Drugs*., 29(6):1198-205, 2011.
31. Tamura K, Shimizu C, Hojo T, Akashi-Tanaka S, Kinoshita T, Yonemori K, Kouno T, Katsumata N, Ando M, Aogi K, Koizumi F, Nishio K, Fujiwara Y. Fc $\gamma$ R2A and 3A polymorphisms predict clinical outcome of trastuzumab in both neoadjuvant and metastatic settings in patients with HER2-positive breast cancer. *Ann Oncol*., 22(6):1302-7, 2011.
32. Kodera. Y., Katanasaka. Y., Kitamura. Y., Tsuda. H., Nishio. K., Tamura. T., Koizumi. F. Sunitinib inhibits lymphatic endothelial cell functions and lymph node metastasis in a breast cancer model through inhibition of vascular endothelial growth factor receptor 3. *Breast Cancer Res*. 2011; 13(3):R66.
33. Arao T, Matsumoto K, Furuta K, Kudo K, Kaneda H, Nagai T, Sakai K, Fujita Y, Tamura D, Aomatsu K, Koizumi F, Nishio K. Acquired drug resistance to vascular endothelial growth factor receptor 2 tyrosine kinase inhibitor in human vascular endothelial cells. *Anticancer Res*. 2011; 31(9): 2787-2796.
34. Nishio M, Yamanaka T, Matsumoto K, Kimura H, Sakai K, Sakai A, Sone T, Horiike A, Koizumi F, Kasahara K, Ohira T, Ikeda N, Saijo N, Arao T, Nishio K. Serum heparan sulfate concentration is correlated with the failure of epidermal growth factor receptor tyrosine kinase inhibitor treatment in patients with lung adenocarcinoma. *J Thorac Oncol*. 2011; 6(11): 1889-1894.
35. Yamauchi M, Yoshino I, Yamaguchi R, Shimamura T, Nagasaki M, Imoto S, Niida A, Koizumi F, Kohno T, Yokota J, Miyano S, Gotoh N. N-cadherin expression is a potential survival mechanism of gefitinib-resistant lung cancer cells. *Am J Cancer Res*. 2011; 1(7): 823-833.
36. Yamada K, Yamamoto N, Yamada Y, Nokihara H, Fujiwara Y, Hirata T, Koizumi F, Nishio K, Koyama N, Tamura T. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors. *Clin Cancer Res*., 17(8):2528-37, 2011.
37. Matsumoto K, Arao T, Hamaguchi T, Shimada Y, Kato K, Oda I, Taniguchi H, Koizumi F, Yanagihara K, Sasaki H, Nishio K, Yamada Y. FGFR2 gene amplification and clinicopathological features in gastric cancer. *Br J Cancer*. 2012; 106(4): 727-732.

38. Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, Okamoto N, Kodaira M, Yonemori K, Shimizu C, Ando M, Masutomi K, Yoshida T, Fujiwara Y, Tamura K.  
Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. *Cancer Sci.* 2012 Sep;103(9):1665-71.
39. Kondo S, Ueno H, Hashimoto J, Morizane C, Koizumi F, Okusaka T, Tamura K.  
Circulating endothelial cells and other angiogenesis factors in pancreatic carcinoma patients receiving gemcitabine chemotherapy. *BMC Cancer.* 2012 Jun 25;12:268
40. Minakata K, Takahashi F, Nara T, Hashimoto M, Tajima K, Murakami A, Nurwidya F, Yae S, Koizumi F, Moriyama H, Seyama K, Nishio K, Takahashi K.  
Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors. *Cancer Sci.*, 103(11):1946-54, 2012.
41. Katanasaka Y, Kodera Y, Kitamura Y, Morimoto T, Tamura T, Koizumi F.  
Epidermal growth factor receptor variant type III markedly accelerates angiogenesis and tumor growth via inducing c-myc mediated angiopoietin-like 4 expression in malignant glioma. *Mol Cancer.* 2013 Apr 25;12:31. doi: 10.1186/1476-4598-12-31.
42. Kondo S, Ueno H, Hosoi H, Hashimoto J, Morizane C, Koizumi F, Tamura K, Okusaka T.  
Clinical impact of pentraxin family expression on prognosis of pancreatic carcinoma. *Br J Cancer.* 2013 Aug 6;109(3):739-46.
43. Murakami H, Yamamoto N, Koizumi F, Nishio K, Yusa W, Koyama N, Tamura T.  
Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer. *Br J Cancer.* 2013 Aug 6;109(3):538-44.
44. Nakadate Y, Kodera Y, Kitamura Y, Shirasawa S, Tachibana T, Tamura T, Koizumi F.  
KRAS Mutation Confers Resistance to Antibody-Dependent Cellular Cytotoxicity of Cetuximab against Human Colorectal Cancer Cells. *Int J Cancer.* 2014 May 1;134(9):2146-55.
45. Nakadate Y, Kodera Y, Kitamura Y, Tachibana T, Tamura T, Koizumi F.  
Silencing of poly(ADP-ribose) glycohydrolase sensitizes lung cancer cells to radiation through the abrogation of DNA damage checkpoint. *Biochem Biophys Res Commun.* 2013 Nov 29;441(4):793-8.
46. Watanabe M, Uehara Y, Yamashita N, Fujimura Y, Nishio K, Sawada T, Takeda K, Koizumi F, Koh Y.  
Multicolor detection of rare tumor cells in blood using a novel flow cytometry-based system. *Cytometry A.* 2014 Mar;85(3):206-13.
47. Taniyama TK, Nokihara H, Tsuta K, Horinouchi H, Kanda S, Fujiwara Y, Yamamoto N, Koizumi F, Yunokawa M, Tamura T.  
Clinicopathological Features in Young Patients Treated for Small-Cell Lung Cancer: Significance of Immunohistological and Molecular Analyses. *Clin Lung Cancer.* 2014 May;15(3):244-7.
48. Murakami A, Takahashi F, Nurwidya F, Kobayashi I, Minakata K, Hashimoto M, Nara T, Kato M, Tajima K, Shimada N, Iwakami S, Moriyama M, Moriyama H, Koizumi F, Takahashi K.  
Hypoxia Increases Gefitinib-Resistant Lung Cancer Stem Cells through the Activation of Insulin-Like Growth Factor 1 Receptor. *PLoS One.* 2014 Jan 28;9(1):e86459.
49. Katanasaka Y, Kodera Y, Yunokawa M, Kitamura Y, Toga W, Tamura T, Koizumi F.  
Synergistic anti-tumor effects of a novel phosphatidylinositol-3 kinase/mammalian target of rapamycin dual inhibitor BGT226 and gefitinib in non-small cell lung cancer cell lines. *Cancer Lett.* 2014 Jun 1;347(2):196-203.
50. Watanabe M, Serizawa M, Sawada T, Takeda K, Takahashi T, Yamamoto N, Koizumi F.

Koh Y.

A novel flow cytometry-based cell capture platform for the detection, capture and molecular characterization of rare tumor cells in blood. *J Transl Med.* 2014 May 23;12:143. doi: 10.1186/1479-5876-12-143.

51. Hashimoto K, Tsuda H, Koizumi F, Shimizu C, Yonemori K, Ando M, Kodaira M, Yunokawa M, Fujiwara Y, Tamura K.  
Activated PI3K/AKT and MAPK pathways are potential good prognostic markers in node-positive, triple-negative breast cancer. *Ann Oncol.* 2014 Oct;25(10):1973-9. doi: 10.1093/annonc/mdu247. Epub 2014 Jul 9.
52. Ando K, Takahashi F, Kato M, Kaneko N, Doi T, Ohe Y, Koizumi F, Nishio K, Takahashi K.  
Tocilizumab, a proposed therapy for the cachexia of Interleukin6-expressing lung cancer. *PLoS One.* 2014 Jul 10;9(7):e102436. doi: 10.1371/journal.pone.0102436. eCollection 2014.
53. Islam R, Koizumi F, Kodera Y, Inoue K, Okawara T, Masutani M.  
Design and synthesis of phenolic hydrazide hydrazones as potent poly(ADP-ribose) glycohydrolase (PARG) inhibitors. *Bioorg Med Chem Lett.* 2014 Aug 15;24(16):3802-6. doi: 10.1016/j.bmcl.2014.06.065. Epub 2014 Jun 27.
54. Koyama N, Saito K, Nishioka Y, Yusa W, Yamamoto N, Yamada Y, Nokihara H, Koizumi F, Nishio K, Tamura T.  
Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib. *BMC Cancer.* 2014 Jul 21;14:530. doi: 10.1186/1471-2407-14-530.
55. Fukai J, Koizumi F, Nakao N.  
Enhanced anti-tumor effect of zoledronic acid combined with temozolomide against human malignant glioma cell expressing O6-methylguanine DNA methyltransferase. *PLoS One.* 2014 Aug 11;9(8):e104538. doi: 10.1371/journal.pone.0104538. eCollection 2014.
56. Sawada T, Omuro Y, Kobayashi T, Hishima T, Koizumi F, Kanemasa Y, Shimoyama T, Sasaki E, Maeda Y.  
Long-term complete remission in a patient with intravascular large B-cell lymphoma with central nervous system involvement. *Onco Targets Ther.* 2014 Nov 18;7:2133-6. doi: 10.2147/OTT.S72596. eCollection 2014.
57. Yagishita S, Fujita Y, Kitazono S, Ko R, Nakadate Y, Sawada T, Kitamura Y, Shimoyama T, Maeda Y, Takahashi F, Takahashi K, Tamura T, Koizumi F.  
Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer. *Mol Cancer Ther.* 2015 Apr 1. [Epub ahead of print]
58. Fujimori H, Hirai T, Inoue K, Koizumi F, Masutani M.  
The Distinctive Properties of Parp and Parg as a Cancer Therapeutic Target. *Journal of Clinical Oncology & Research*
59. Yunokawa M, Tsuta K, Tanaka T, Nara E, Koizumi F, Ito J, Sekine S, Fujiwara Y, Tamura K.  
Back with a Vengeance: Microvascular Tumor Embolism. *Am J Med.* 2015 Apr 23. pii: S0002-9343(15)00344-7. doi: 10.1016/j.amjmed.2015.04.004. [Epub ahead of print] No abstract t available.
60. Sasaki Y, Hozumi M, Fujimori H, Murakami Y, Koizumi F, Inoue K, Masutani M.  
PARG inhibitors and functional PARG inhibition models. *Curr Protein Pept Sci.* 2016 Apr 19.

61. Morimoto A, Mogami T, Watanabe M, Iijima K, Akiyama Y, Katayama K, Futami T, Yamamoto N, Sawada T, Koizumi F, Koh Y  
High-Density Dielectrophoretic Microwell Array for Detection, Capture, and Single-Cell Analysis of Rare Tumor Cells in Peripheral Blood. *PLoS One*. 2015 Jun 24;10(6):e0130418
62. Sawada T, Watanabe M, Fujimura Y, Yagishita S, Shimoyama T, Maeda Y, Kanda S, Yunokawa M, Tamura K, Tamura T, Minami H, Koh Y, Koizumi F.  
Sensitive cytometry based system for enumeration, capture and analysis of gene mutations of circulating tumor cells. *Cancer Sci*. 2016 Mar;107(3):307-14.
63. Okuma HS, Koizumi F, Hirakawa A, Nakatochi M, Komori O, Hashimoto J, Kodaira M, Yunokawa M, Yamamoto H, Yonemori K, Shimizu C, Fujiwara Y, Tamura K.  
Clinical and microarray analysis of breast cancers of all subtypes from two prospective preoperative chemotherapy studies. *Br J Cancer*. 2016 Aug 9;115(4):411-9.
64. Sawada T, Araki J, Yamashita T, Masubuchi M, Chiyoda T, Yunokawa M, Hoshi K, Tao S, Yamamura S, Yatsushiro S, Abe K, Kataoka M, Shimoyama T, Maeda Y, Kuroi K, Tamura K, Sawazumi T, Minami H, Suda Y, Koizumi F.  
Prognostic Impact of Circulating Tumor Cell Detected Using a Novel Fluidic Cell Microarray Chip System in Patients with Breast Cancer. *EBioMedicine*. 2016 Sep;11:173-182
65. Sasaki Y, Hozumi M, Fujimori H, Murakami Y, Koizumi F, Inoue K, Masutani M.  
PARG Inhibitors and Functional PARG Inhibition Models. *Curr Protein Pept Sci*. 2016;17(7):641-653.
66. Kageyama SI, Nihei K, Karasawa K, Sawada T, Koizumi F, Yamaguchi S, Kato S, Hojo H, Motegi A, Tsuchihara K, Akimoto T.  
Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients. *Oncotarget*. 2018 Apr 10;9(27):19368-19378
67. Sawada T, Hilhorst R, Rangarajan S, Yoshida M, Tanabe Y, Tamura T, Kinoshita T, Shimoyama T, Beuningen R, Ruijtenbeek R, Tsuda H and Koizumi F.  
Inactive immune pathways in triple negative breast cancers that showed resistance to neoadjuvant chemotherapy as inferred from kinase activity profiles. *Oncotarget*. 2018 Sep 28;9(76)
68. Sasaki Y, Fujimori H, Hozumi M, Onodera T, Nozaki T, Murakami Y, Ashizawa K, Inoue K, Koizumi F, Masutani M. Dysfunction of poly(ADP-ribose) glycohydrolase induces a synthetic lethal effect in dual specificity phosphatase 22-deficient lung cancer cells. *Cancer Res*. 2019 May 29. pii: canres.1037.2018. doi: 10.1158/0008-5472.CAN-18-1037. [Epub ahead of print]